Theranexus: funding of €4.7 million for PickASO

(Boursier.com) — Theranexus , Diverchim and INSERM benefit from funding of 4.7 million euros as part of the ‘Innovations in Biotherapies and Bioproduction’ call for projects from France 2030, to develop a new antisense oligonucleotide. Leaders of the PickASO project, winner of the call for projects, Theranexus, Diverchim and the ARNA laboratory at INSERM therefore benefit from this state funding in order to develop “a revolutionary therapy for activating autophagy”. The PickASO consortium is led by Theranexus, specialized in rare neurological diseases, and will include Diverchim, an expert in the synthesis of active pharmaceutical ingredients, and the ARNA laboratory of INSERM, the leading French academic player in the field of antisense oligonucleotides (ASO). .

This financing of 4.7 ME over a period of 3 years is allocated by the State and operated on its behalf by Bpifrance in the form of grants and repayable advances. It will enable the development, by Theranexus and until its entry into clinical development, of an antisense oligonucleotide, an innovative drug candidate targeting TFEB, the protein recognized as controlling autophagy. To this end, the project combines the skills in molecular biology, neuroscience and drug development of Theranexus with those relating to RNA chemistry of the ARNA team and the expertise in industrial synthesis of active ingredients of Diverchim.